Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Can-Fite BioPharma ( (CANF) ) is now available.
On August 28, 2025, Can-Fite BioPharma Ltd. announced its financial results for the first half of 2025 and provided updates on its drug development programs. The company released unaudited interim condensed consolidated financial statements as of June 30, 2025. These announcements are significant as they provide insights into the company’s financial health and progress in drug development, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (CANF) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Underperform.
The overall stock score reflects significant financial challenges and bearish technical indicators. The company’s persistent financial losses and reliance on external financing are major concerns, compounded by negative technical signals. The absence of profitability metrics further underscores the risks associated with this stock.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is an advanced clinical-stage biopharmaceutical company based in Israel, specializing in the development of orally bioavailable small molecule therapeutic products targeting cancer, liver, and inflammatory diseases. The company’s platform technology focuses on the A3 adenosine receptor (A3AR), which is expressed in pathological cells such as inflammatory and cancer cells. Can-Fite’s product pipeline includes drug candidates like CF101, CF102, and CF602, aimed at treating conditions such as psoriasis, hepatocellular carcinoma, and erectile dysfunction.
Average Trading Volume: 189,714
Technical Sentiment Signal: Sell
Current Market Cap: $14.21M
For an in-depth examination of CANF stock, go to TipRanks’ Overview page.